As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...